Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

408.18 +2.91 (+0.72%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
55 56 Next >
2 Potentially Explosive Stocks to Buy in May
These companies should outpace the overall market for years. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy in May
You'll want to hold onto these innovative companies for the long term. 
Via The Motley Fool
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday. 
Via Investor's Business Daily
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock
The bull case for the cystic fibrosis treatment maker is as strong as ever. 
Via The Motley Fool
7 Reasons to Buy Vertex Pharmaceuticals Stock Now
It's not too late to invest in this top biotech stock. 
Via The Motley Fool
Analyst Expectations for Vertex Pharmaceuticals's Future
Via Benzinga
Baird Maintains Neutral Rating for Vertex Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Vertex Pharmaceuticals, Transocean, And 'One Of The Best Companies' In Staples: CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners chose Transocean Ltd (NYSE: RIG), after the company reported 
Via Benzinga
Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?
Vertex dominates the cystic fibrosis market today. 
Via The Motley Fool
2 Supercharged Stocks to Buy for 2023 and Hold for at Least 10 Years
These businesses are leaders in their respective industries, but aren't close to done growing. 
Via The Motley Fool
2 Incredible Growth Stocks That Could Turn $20,000 Into $100,000 by 2030
These growth stocks each have a competitive edge in their respective industries. 
Via The Motley Fool
Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie
One big drugmaker's pain translates into another big drugmaker's gain. 
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q1 2023 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Vertex Pharmaceuticals Keeps Its Outlook Despite Beating Views, And Dives
Vertex expects $9.55 billion to $9.7 billion in full-year product sales. 
Via Investor's Business Daily
Earnings Outlook For Vertex Pharmaceuticals
Via Benzinga
2 Growth Stocks That Could Double in 5 Years
Both of these companies did more than that in the past five years. 
Via The Motley Fool
Vertex Reports First Quarter 2023 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
The Best Stocks to Invest $5,000 in Right Now
These appear to be the ideal stocks in times like these. 
Via The Motley Fool
2 Stocks That Could Turn $200,000 Into $1 Million by the Time You Retire
Planning for the long term starts now. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
Don't let the temporary headwinds for two of these stocks fool you. 
Via The Motley Fool
Earnings Scheduled For May 1, 2023
Companies Reporting Before The Bell • TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.37 per share on revenue of $3.38 million. 
Via Benzinga
ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug
ImmunoGen Inc (NASDAQ: IMGN) shares are surging Friday morning following its impressive first-quarter performance. 
Via Benzinga
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch. 
Via InvestorPlace
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Healthcare Stocks That Could Help Make You a Fortune
These companies are top players in their fields. 
Via The Motley Fool
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.